Tag: Biosimilars
FDA approves Accord BioPharma’s biosimilar ‘IMULDOSA’ to treat chronic inflammatory conditions
Accord BioPharma (A division of Intas Pharmaceuticals) anticipates a commercial launch of IMULDOSA in the first half of 2025
Biocon Biologics report reveals strategies to boost biosimilar adoption in LMICs
GaBI Journal publishes peer-reviewed study highlighting six policy recommendations for expanding access to affordable healthcare
CPHI Pharma Awards 2024 recognize leaders and innovations in the pharma...
Fourteen categories celebrate groundbreaking achievements and introduce new honors for emerging leaders
IQVIA conducts over 45 vaccine studies in India during last 5...
The company’s success in vaccine trials is driven by its extensive site network, comprising over 130 locations across India
Biocon Biologics secures market entry for its Bmab 1200 Biosimilar in...
Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan
Eli Lilly’s Tirzepatide approved by NMPA in China, boosting market position
Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence
Biocon reports 30% revenue increase and ₹660 crore net profit in...
Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success
Zydus Lifesciences secures COFEPRIS approval to market MamitraTM in Mexico for...
With the approval of MamitraTM, Zydus aims to provide affordable cancer treatments for HER2-positive breast and gastric cancer patients
EMA approves Biocon Biologics’ new mAbs facility in India
European Medicines Agency also renews GMP certifications for Biocon's manufacturing sites in India and Malaysia, enhancing global biosimilars supply
Biocon’s biosimilars revenue crosses milestone of US $1 Billion in FY...
The company garnered an overall revenue of Rs 15,621 Crore in FY24, marking a remarkable 35% growth compared to the previous year